Datapoint: Alvotech Aims to Get Humira Biosimilar to Market Sooner With Lawsuit

Though Humira biosimilars are set to launch in the U.S. in 2023, biopharmaceutical manufacturer Alvotech is aiming to get its biosim, AVT02, to market faster via a federal lawsuit, per a May 11 press release. Alvotech says AbbVie engaged in “inequitable conduct” to gain its Humira patents, among other allegations centered around the drugmaker’s attempt to “overwhelm” the company with legal issues and create a “wrongful monopoly.” For the treatment of rheumatoid arthritis, the Humira pen holds covered or better status for 70% of all insured lives under the pharmacy benefit. It is classified as a specialty drug for 29.8% of covered lives.

SOURCE: MMIT Analytics, as of 5/12/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 6

Datapoint: Moda Health to Expand to Idaho

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 5

Datapoint: North Carolina Delays Launch of New Medicaid MCOs

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 4

Datapoint: FDA Approves Avastin Biosimilar

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today